Trial Profile
A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 05 Feb 2020 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 05 Dec 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.